OpGen

OverviewSuggest Edit

OpGen is uniquely positioned to address the rising antibiotic resistance crisis and is harnessing the power of informatics and genomic analysis to provide complete solutions to protect patients in hospitals and healthcare networks. Using its large and ever-growing Acuitas Lighthouse® Database of pathogens from around the world, the Company is developing disruptive technologies aimed to shift the paradigm for managing infectious diseases.

Through its CLIA-certified clinical laboratory services, OpGen provides rapid detection and analysis of antibiotic resistance and high-resolution microbial sequence analysis. The Company's FDA-cleared, IVD products rapidly identify pathogens in positive blood cultures.

TypePublic
Founded2002
HQGaithersburg, MD, USMap
Websiteopgen.com
Employee Ratings3More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)44(+26%)
Revenue (FY, 2020)$4.2 M(+21%)
Share Price (May 2022)$0.3(-3%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at OpGen

Timothy Dec

Timothy Dec

Chief Financial Officer
Vadim Sapiro

Vadim Sapiro

Chief Information Officer
Johannes Bacher

Johannes Bacher

Chief Operating Officer
Faranak Atrzadeh

Faranak Atrzadeh

Chief Marketing and Scientific Affairs Officer
Derek Joesting

Derek Joesting

Senior Vice President, US Sales
Arne Materna

Arne Materna

Managing Director & CEO: Ares Genetics
Show more

OpGen Office Locations

OpGen has offices in Gaithersburg, Rockville, Wien and Holzgerlingen
Gaithersburg, MD, US (HQ)
708 Quince Orchard Rd
Rockville, MD, US
9717 Key W Ave #100
Wien, AT
Karl-Farkas-Gasse 18
Holzgerlingen, DE
Max-Eyth-Straße 42
Show all (4)

OpGen Financials and Metrics

OpGen Revenue

OpGen's revenue was reported to be $4.21 m in FY, 2020
USD

Revenue (Q1, 2021)

829.7k

Net income (Q1, 2021)

(14.9m)

EBIT (Q1, 2021)

(6.3m)

Market capitalization (13-May-2022)

13.5m

Closing stock price (13-May-2022)

0.3

Cash (31-Mar-2021)

39.4m

EV

(2.6m)
OpGen's current market capitalization is $13.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

3.2m4.0m3.2m2.9m3.5m4.2m

Cost of goods sold

1.2m1.7m1.6m

Gross profit

2.0m2.4m1.6m

Gross profit Margin, %

63%59%50%
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

472.2k375.1k980.8k1.1m1.2m759.7k771.8k703.2k745.1k846.2k788.9k552.2k1.0m1.0m648.2k616.9k1.2m829.7k

Cost of goods sold

115.4k48.2k562.7k346.0k337.0k400.0k425.0k392.8k448.4k342.8k

Gross profit

356.8k326.9k418.1k730.7k845.8k359.7k346.8k310.4k296.7k503.4k

Gross profit Margin, %

76%87%43%68%72%47%45%44%40%59%
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

7.8m4.1m1.8m4.6m2.7m13.4m

Accounts Receivable

678.6k542.4k809.5k373.9k567.8k653.1k

Prepaid Expenses

572.5k329.6k311.6k292.9k396.8k1.4m

Inventories

826.0k692.4k533.4k543.7k473.0k1.5m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

631.7k10.2m11.2m4.0m8.0m4.3m1.7m211.7k4.9m10.3m7.4m4.7m6.0m3.1m626.4k11.5m12.9m39.4m

Accounts Receivable

92.0k214.0k553.9k641.6k871.6k446.7k379.2k411.8k470.0k591.5k516.5k315.6k813.3k772.9k377.3k165.9k231.4k486.0k

Prepaid Expenses

210.1k490.2k538.3k456.0k561.7k478.7k268.0k423.5k340.9k238.0k525.5k457.9k162.2k178.4k533.4k264.0k810.4k1.5m

Inventories

320.8k347.5k1.2m924.3k844.3k830.2k643.0k578.9k461.1k509.1k614.4k529.8k498.9k567.4k468.4k436.7k2.9m1.4m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(17.4m)(19.2m)(15.4m)(13.4m)(12.4m)(26.2m)

Depreciation and Amortization

624.7k656.0k669.1k730.9k921.4k2.3m

Inventories

424.5k(20.2k)161.0k(11.3k)70.3k(410.3k)

Accounts Payable

196.4k(53.2k)(563.4k)89.5k(503.5k)(481.5k)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(2.6m)(8.0m)(12.6m)(4.5m)(9.6m)(14.4m)(5.0m)(9.2m)(12.5m)(3.0m)(6.4m)(9.6m)(3.9m)(6.4m)(9.9m)(3.9m)(11.4m)(14.9m)

Depreciation and Amortization

106.1k207.2k392.4k168.4k330.0k494.8k159.9k324.4k499.7k156.3k317.7k508.2k223.1k451.0k687.1k228.5k913.4k546.9k

Inventories

45.3k4.1k288.1k(112.9k)(109.5k)113.6k49.4k113.5k231.2k24.9k(81.3k)3.2k44.5k(23.8k)74.4k36.3k(373.4k)(448.5k)

Accounts Payable

(319.5k)238.4k(814.9k)(80.3k)(385.0k)(349.8k)(215.4k)674.6k(293.4k)(63.0k)(219.6k)(494.0k)(31.5k)(301.4k)314.6k(627.0)(487.3k)(570.9k)
show all
USDQ1, 2015

Financial Leverage

-0.3 x
Show all financial metrics

OpGen Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

Learn more about our premium products
SecurityScorecard logo

OpGen Online and Social Media Presence

OpGen's Trends

Embed Graph

OpGen News and Updates

May 12, 2022

OpGen Reports First Quarter 2022 Financial Results and Provides Business Update

ROCKVILLE, Md., May 12, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2022 financial and operating results. M…
April 05, 2022

OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

ROCKVILLE, Md., April 05, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that, following the successful completion of a re…
March 29, 2022

OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

ROCKVILLE, Md., March 29, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its fourth quarter 2021 and full-year 2021 financ…
March 15, 2022

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter and full year 2021 financial results after the close of the U.S. financial markets on Tuesday, Marc…
February 10, 2022

OpGen Announces Successful Completion of Unyvero A30 Development Milestone

ROCKVILLE, Md., Feb. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary Curetis has successfully met a key milestone in t…
January 18, 2022

OpGen to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022

ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today it is participating in Edison Group’s Open House Event, scheduled to …
Show more

OpGen Blogs

April 28, 2022

OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time

OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time Content Import Thu, 04/28/2022 - 07:30 OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time …
April 20, 2022

OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally

OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally Content Import Wed, 04/20/2022 - 07:30 OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally 04.20.22 General …
February 10, 2022

OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

Publication demonstrates FDA cleared Acuitas AMR Gene Panel detects and differentiates a broad range of 28 AMR markers that can be associated with up to 9 antimicrobial classes Provides results at least a day earlier than traditional methods to guide patient management and support antibiotic
December 08, 2021

OpGen Announces Results of Special Meeting of Stockholders

OpGen Announces Results of Special Meeting of Stockholders Content Import Wed, 12/08/2021 - 16:33 OpGen Announces Results of Special Meeting of Stockholders 12.08.21 This release is a backfill from a News Wire Earnings ROCKVILLE, Md.…
November 11, 2021

OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update

Total Revenue for Q3 2021 was approximately $1.2 million Cash as of September 30, 2021 , was approximately $25.4 million , up significantly from the $13.4 million at year-end 2020 Cash balance was further strengthened significantly by $15 million financing completed in October Conference call to be
October 18, 2021

OpGen Announces Closing of $15 Million Registered Direct Offering

ROCKVILLE, Md. , Oct. 18, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the closing of its previously announced
Show more

 OpGen Frequently Asked Questions

  • When was OpGen founded?

    OpGen was founded in 2002.

  • Who are OpGen key executives?

    OpGen's key executives are Timothy Dec, Vadim Sapiro and Johannes Bacher.

  • How many employees does OpGen have?

    OpGen has 44 employees.

  • What is OpGen revenue?

    Latest OpGen annual revenue is $4.2 m.

  • What is OpGen revenue per employee?

    Latest OpGen revenue per employee is $95.8 k.

  • Who are OpGen competitors?

    Competitors of OpGen include DiaSorin, Xenon Pharmaceuticals and Blue Health Intelligence.

  • Where is OpGen headquarters?

    OpGen headquarters is located at 708 Quince Orchard Rd, Gaithersburg.

  • Where are OpGen offices?

    OpGen has offices in Gaithersburg, Rockville, Wien and Holzgerlingen.

  • How many offices does OpGen have?

    OpGen has 4 offices.